Prostate cancer

Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.

25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off.

Following its approval in Scotland 2 weeks ago, a new treatment will now be available on the NHS in England for some people with prostate cancer.

The Scottish Medicines Consortium (SMC) has approved 4 new cancer drugs for use on the NHS in Scotland to treat some lung, breast and prostate cancers.

A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

All men with suspected prostate cancer should be offered a specialist MRI scan, before a biopsy. That’s the new recommendation, but is the NHS ready?

A prostate cancer drug won’t be offered on the NHS any earlier in the treatment plans of patients living with the disease in England.

Our scientists have uncovered a new marker that’s found on treatment-resistant prostate cancer cells.